Needle-free MySugarWatch continuous glucose monitor for type 2 diabetes offers equivalent of 168 fingerprick tests a day from £48 (US$58) a month
MySugarWatch, which is a UK licensee of Nemaura Medical, has been promoting its non-invasive continuous glucose monitor in the Daily Mail, a British newspaper that has an average circulation figure that frequently hovers around the one-million mark. The needle-free MySugarWatch device, which is only for people with type 2 diabetes, does away with the need for a skin-piercing lancet by utilizing a transmitter and a sensor. The CGM is simply attached to the upper arm and a “non-perceptible electric current” is then responsible for attracting glucose molecules from the interstitial fluid as part of the measuring process.
There are some interesting claims made on the official MySugarWatch site that will certainly appeal to those wondering how to manage their type 2 diabetes. For instance, as mentioned above, with the ability to transmit glucose level measurements to a connected smartphone via the MSW app, users can receive the equivalent information of 168 potentially painful fingerpricks over a period of 14 hours. A conventional glucose meter, test strips, and lancets are provided in the monthly packages, as some calibration is still required. But after that, MySugarWatch users can apparently expect 500-600 blood glucose measurements with three continuous days of wear, thanks to the presence of the licensed sugarBEAT CGM.
Unsurprisingly, the MySugarWatch is not exactly cheap, and it comes as part of a monthly subscription package that lasts for 12 months (although there is a generous 14-day cooling off period). For £48 a month (roughly US$58; £576 (US$693) a year) people with type 2 diabetes can apply for the “Discovery” package that contains all the components required for non-invasive glucose monitoring. A “Gold” membership for £78 a month (about US$94; £936 (US$1,126) a year) includes five disposable MSW skin patch sensors as opposed to the three you get with the cheaper package, and it features the delivery of an HbA1c home test kit every six months to check overall progress.
Lastly, there is the MySugarWatch Platinum package that costs £98 a month (almost US$118; £1,176 (US$1,415) a year). For this money, the subscriber gets 10 sensors a month and some face-to-face consultation time each month for the first three months of the subscription. There are some other perks too for Platinum members that can be browsed through via the sign-up page. It’s somewhat early days for the MySugarWatch company, which is based in Jersey, although there are a couple of video testimonials promoted on the site with users singing the praises of the needle-free glucose monitor. Availability is currently for users in the UK, although Nemaura has made an application for sugarBEAT’s premarket approval with the FDA in the US.
MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail
May 17, 2022 08:00 ET | Source: Nemaura Medical, Inc
Loughborough, England, May 17, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that its UK licensee, MySugarWatch, has continued its large scale awareness campaign for the Company’s sugarBEAT non-invasive continuous glucose monitor by commencing a direct-to-consumer campaign in one of the UK’s largest daily newspaper, Daily Mail.
MySugarWatch’s Daily Mail campaign is designed to reach its more than 1.2 million daily readers, inviting them to learn more about glucose management as part of sugarBEAT commercialization by Nemaura’s UK licensee. The Daily Mail ads are part of a previously announced wider campaign, which also targets media outlets geared toward both consumers and professionals.
Faz Chowdhury, Ph.D., Nemaura’s CEO commented, “Embarking on the consumer phase of our UK licensee’s campaign in support of the commercialization efforts around sugarBEAT is very exciting and we are looking forward to continuing our support for our licensee. Our commitment to supporting MySugarWatch’s success remains strong, and we look forward to the opportunity to provide what is potentially a game-changing non-invasive CGM, to potential users in the UK.”
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and commercializing wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.